Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

558
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
558
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Neural Regulation01:37

Neural Regulation

44.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
44.0K
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

4.7K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.7K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-Term Exposure to Air Pollution and Incidence of Parkinson's Disease: A Danish Nationwide Administrative Cohort Study.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Transcervical, Transabdominal and Transvaginal Chorionic Villus Sampling for Prenatal Diagnosis in Zagreb, Croatia: A Prospective Single-Operator Study on 5500 Cases.

Diagnostics (Basel, Switzerland)·2025
Same author

Genetic and Sonographic Insights into First-Trimester Fetal Cystic Hygroma: A Retrospective 30-Year Analysis Using 3D/4D Ultrasound and Cytogenetic Evaluation in Croatia (1993-2023).

Genes·2025
Same author

Development of a diagnostic checklist to identify functional cognitive disorder versus other neurocognitive disorders.

BMJ neurology open·2025
Same author

Long-term exposure to air pollution and road traffic noise and incidence of dementia in the Danish Nurse Cohort.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2024
Same author

Perspectives on the diagnosis and management of functional cognitive disorder: An international Delphi study.

European journal of neurology·2024

Related Experiment Video

Updated: Mar 17, 2026

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
06:07

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease

Published on: June 23, 2023

2.4K

Parkinson's disease.

Raphael Béné1, Sonja Antić, Mislav Budisić

  • 1University Department of Neurology, Reference Center for Neurovascular Disorders, Ministry of Health and Social Welfare, Republic of Croatia, Sestre milosrdnice University Hospital, Zagreb, Croatia. Raphaelbene.hr@gmail.com

Acta Clinica Croatica
|January 9, 2010
PubMed
Summary

Parkinson's disease involves the loss of brain cells, leading to motor and non-motor symptoms. Current treatments like L-dopa manage symptoms but don't halt disease progression.

More Related Videos

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.6K
Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
05:38

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model

Published on: January 7, 2019

19.2K

Related Experiment Videos

Last Updated: Mar 17, 2026

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
06:07

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease

Published on: June 23, 2023

2.4K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.6K
Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
05:38

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model

Published on: January 7, 2019

19.2K

Area of Science:

  • Neurology
  • Neuroscience
  • Pathology

Background:

  • Parkinson's disease (PD) is a common neurodegenerative disorder.
  • It is characterized by the loss of dopaminergic neurons in the substantia nigra.
  • Neuropathologically, PD features Lewy bodies, primarily composed of alpha-synuclein and ubiquitin.

Purpose of the Study:

  • To review the current understanding of Parkinson's disease.
  • To discuss the known genetic and environmental factors contributing to PD.
  • To outline the characteristic motor and non-motor symptoms of PD.

Main Methods:

  • Literature review of Parkinson's disease.
  • Analysis of neuropathological hallmarks.
  • Summary of clinical manifestations.
  • Overview of current therapeutic strategies.

Main Results:

  • Parkinson's disease pathogenesis involves dopaminergic neuron degeneration.
  • Lewy bodies (alpha-synuclein, ubiquitin) are key pathological markers.
  • Motor symptoms include bradykinesia, rigidity, tremor, and postural instability.
  • Non-motor symptoms are also prevalent in PD patients.

Conclusions:

  • The exact mechanisms of Parkinson's disease development require further elucidation.
  • Effective management of Parkinson's disease relies on symptomatic treatments.
  • Current therapies include L-dopa, dopaminergic agents, MAO-B inhibitors, COMT inhibitors, amantadine, and anticholinergics.